bismuth subcitrate
Selected indexed studies
- Colloidal bismuth subcitrate. (S Afr Med J, 1988) [PMID:3291158]
- Bismuth subcitrate as treatment of diarrhea in fragile patients with SARS-CoV-2 infection. (Med Clin (Barc), 2022) [PMID:36123202]
- Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. (Drugs, 1988) [PMID:3053124]
_Worker-drafted node — pending editorial review._
Connections
bismuth subcitrate is a side effect of
Sources
- Colloidal bismuth subcitrate. (1988) pubmed
- Bismuth subcitrate as treatment of diarrhea in fragile patients with SARS-CoV-2 infection. (2022) pubmed
- Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. (1988) pubmed
- Safety and pharmacokinetics: colloidal bismuth subcitrate. (1991) pubmed
- The mode of action of colloidal bismuth subcitrate. (1991) pubmed
- Reversible nephrotoxicity after overdose of colloidal bismuth subcitrate. (2001) pubmed
- Clinical indications and efficacy of colloidal bismuth subcitrate. (1991) pubmed
- Acute renal failure after overdose of colloidal bismuth subcitrate. (2005) pubmed
- Topically active drugs in the treatment of peptic ulcers. Focus on colloidal bismuth subcitrate and sucralfate. (1992) pubmed
- Colloidal bismuth subcitrate in peptic ulcer--a review. (1987) pubmed